Partners and Sponsors

IARC’s Mission: Cancer research for cancer prevention The International Agency for Research on Cancer (IARC) is the specialized cancer agency of the World Health Organization. The objective of the IARC is to promote international collaboration in cancer research. The Agency is inter-disciplinary, bringing together skills in epidemiology, laboratory sciences and biostatistics to identify the causes of cancer so that preventive measures may be adopted and the burden of disease and associated suffering reduced. A significant feature of the IARC is its expertise in coordinating research across countries and organizations; its independent role as an international organization facilitates this activity. The Agency has a particular interest in conducting research in low and middle-income countries through partnerships and collaborations with researchers in these regions. Causes and prevention of cancer Emphasis is placed on elucidating the role of environmental and lifestyle risk factors and studying their interplay with genetic background in population-based studies and appropriate experimental models. This emphasis reflects the understanding that most cancers are, directly or indirectly, linked to environmental factors and thus are preventable. The IARC Monographs Programme is a core element of the Agency’s portfolio of activities, with international expert working groups evaluating the evidence of the carcinogenicity of specific exposures. The Agency is also committed to studying approaches for the early detection of cancer and in evaluating prevention strategies. A global reference for cancer information The IARC has an important role in describing the burden of cancer worldwide, through co-operation with and assistance to cancer registries and in monitoring geographical variations and trends over time. Key publications include the Cancer Incidence in Five Continents series and GLOBOCAN. The classification of human tumours as reported in the WHO “Blue Book” series is an additional resource of value to cancer researchers and clinicians worldwide. In all cases the Agency strives to make its findings available to the widest possible audience. Global cancer biobank One of the products of IARC’s coordinating role is an increasingly important biobank with currently approximately 6 million samples from 600 000 subjects in total. This resource permits the application of innovative laboratory-based methodologies to study the causes, early detection and prevention of cancer through collaborative studies with many international partners. Education and training A core part of the Agency’s mission is education and training of cancer researchers worldwide. This is achieved through fellowships, courses and publications. Priority is given to training researchers from low and middle-income countries in the areas of cancer epidemiology and cancer registration. Producing evidence-based science for global cancer control policies The close working relationship between IARC and its parent organization, WHO, allows the research findings of the Agency to be translated effectively into timely policies for cancer control. This is manifest, for example, in co-operation in terms of reduction in tobacco use, implementation of vaccination against viruses associated with cancer causation, or in assessing the effectiveness of intervention strategies. IARC is not involved directly in implementation of control measures, nor does it conduct research on treatment or care of cancer patients.

Geneva, a dynamic hub of knowledge linking local experts in key industry sectors The Geneva Convention Bureau is proudly supporting the organisation of the World Cancer Congress.

The République et Canton de Genève is proudly supporting the organisation of the World Cancer Congress.

Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.

KWF Kankerbestrijding/KWF Dutch Cancer Society was founded in 1949. Back then, the prognosis for cancer patients was bleak: 5 years post-diagnosis, only 1 out of 4 cancer patients was still alive. Nowadays, this number has increased to 2 out of 3 . We thank our donors, whose generous donations has enabled researchers to detect, understand and treat cancer better. However, despite these promising numbers, our task is not finished. The increasing complexity of oncology is accompanied by new challenges and questions. If more cancer patients can be cured, or survive longer, how can we optimize their quality of life? How can we stimulate better treatment for rare and hard-to-treat tumours? And how can we prevent cancer? The patient is key Through our actions, we support patients in every aspect of their life. For people who have not yet been diagnosed with cancer, as well as for patients who can’t be cured. Our main goals are: • To prevent cancer wherever we can. • To stimulate better treatment for every type of cancer. • To aim for a better quality of life for (recovered) patients and their loved ones. • To ensure that high quality palliative care is available for all patients. Through stimulation of focused scientific research, policy making, knowledge transfer and collaboration with our stakeholders, KWF is dedicated to improving the lives of cancer patients and their loved ones. Our organisational structure enables us to respond quickly to developments in society and research.. There are enormous challenges ahead of us. KWF can’t face these alone. Therefore, we join forces with (inter)national stakeholders to achieve our goals. With the support of society, which includes 100,000 volunteers and almost 1 million donors. We work together for a better life with and without cancer; this is what we stand for!

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.

The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Cancer Awareness Campaigns: Jhpiego work in country programs to conduct community outreach and education campaigns for cervical cancer prevention. The awareness campaigns are targeted to women in the catchment areas where VIA and Cryotherapy services have been set up. Advocacy and awareness campaigns have been conducted in Ghana (in collaboration with Rotary Club), Malawi, Philippines, Thailand, Guyana, etc. Jhpiego also participates in and receives funding support from the Tour of Hope, which raises funds for education and healthcare support for the prevention and treatment of cervical cancer in Asia. Cancer Prevention: Jhpiego provides technical assistance to countries for the introduction and expansion of cervical cancer prevention programs, with a focus on the Single Visit Approach, which combines screening with Visual Inspection with Acetic Acid (VIA), with the offer of Cryotherapy at the same visit. Jhpiego implements comprehensive prevention programs, taking into account advocacy and policies, training, service delivery, referral systems, community education, and monitoring and evaluation. Jhpiego is currently implementing programs Peru, Guyana, Indonesia, Ivory Coast, Mozambique, South Africa, Tanzania, Thailand and the Philippines. Jhpiego has also implemented programs in Ghana and Malawi. Several Cancer Research & Publications. Education & Training: Jhpiego has organized and conducted three Regional VIA and Cryotherapy Clinical Training Courses; two in Asie (Thailand, Philippines) and one in Africa (Malawi). In addition, as a component of ongoing programs, Jhpiego routinely provides VIA and Cryotherapy training and follow up supervision and coaching support for health care providers Ghana, Malawi, Peru, Guyana, Indonesia, Ivory Coast, Mozambique, South Africa, Tanzania, Thailand and the Philippines.